From MSO asset purchases to SBA-backed seller notes, this guide covers the deal structures buyers and sellers use to close compliant, bankable cosmetic surgery transactions in the $1M–$5M revenue range.
Acquiring or selling a cosmetic surgery center requires deal structures that go beyond standard business purchases. Because most states prohibit non-physicians from owning or controlling a medical professional corporation under corporate practice of medicine (CPOM) laws, transactions typically involve a bifurcated structure separating the clinical entity from the business operations. Add to this the challenge of physician key-man dependency, malpractice tail obligations, and patient data sensitivity, and it becomes clear why deal structure choices in this space carry outsized legal and financial consequences. This guide walks through the three most common transaction structures used in lower middle market cosmetic surgery acquisitions — asset purchases with MSO layering, stock purchases with rollover equity and earnouts, and seller-financed SBA hybrid deals — along with negotiation tactics and answers to the most frequently asked questions from both buyers and sellers.
Find Cosmetic Surgery Center Businesses For SaleAsset Purchase with MSO Structure
The buyer acquires the tangible and intangible assets of the cosmetic surgery practice — equipment, patient records (with consent), goodwill, trade name, and contracts — while a Management Services Organization (MSO) is established to hold the non-clinical business assets and employ non-physician staff. A separate physician-owned professional corporation (PC) retains clinical control and employs the licensed providers. The MSO contracts with the PC for management services at a fair-market-value fee, allowing the non-physician buyer to extract economic value without violating CPOM laws.
Pros
Cons
Best for: Non-physician buyers, private equity platforms using MSO rollups, or entrepreneurial operators acquiring a cosmetic surgery center in a CPOM-restrictive state such as California, Texas, or New York.
Stock Purchase with Seller Rollover Equity and Earnout
The buyer acquires 80–90% of the equity in the seller's existing corporate entity (or newly restructured holding company), with the selling physician retaining 10–20% rollover equity. An earnout provision ties a portion of the purchase price — typically 15–25% — to the practice maintaining specified revenue or EBITDA thresholds over a 2–3 year post-close period. The seller remains active clinically during the earnout window to ensure patient and revenue continuity, then transitions out on a defined schedule.
Pros
Cons
Best for: Strategic acquirers and PE platforms pursuing add-on acquisitions where the selling surgeon has agreed to a 2–3 year clinical transition and the practice has a clean compliance and malpractice history.
Seller-Financed Deal with SBA 7(a) Loan
The buyer finances 70–80% of the purchase price through an SBA 7(a) loan (up to $5M) using the practice's assets and cash flow as collateral. The selling physician provides a subordinated seller note covering 10–20% of the purchase price, with repayment terms of 5–7 years at a negotiated interest rate. A short seller employment or consulting agreement — typically 12–24 months — ensures clinical continuity during the loan's early repayment period. SBA lenders require the seller note to be on full standby for at least 24 months.
Pros
Cons
Best for: Individual buyers — including physician entrepreneurs and MSO operators — acquiring a $1M–$3M revenue cosmetic surgery center where the seller is willing to carry a note and remain engaged clinically for 12–24 months post-close.
PE Add-On Acquisition of a Multi-Physician Cosmetic Surgery Center
$4,200,000
$3,570,000 (85%) cash at close from PE platform equity; $630,000 (15%) seller rollover equity in the acquiring holdco; plus a $500,000 earnout payable over 24 months contingent on the practice maintaining 90% of trailing 12-month revenue post-close.
Stock purchase structured through a newly created MSO/PC bifurcation. Selling surgeon signs a 2-year employment agreement at $350,000 base salary. Rollover equity vests ratably over 24 months. Earnout measured on net collected revenue, not bookings. Tail malpractice insurance funded by seller at close covering all pre-closing claims.
SBA 7(a) Acquisition by a Physician Entrepreneur Using MSO Structure
$2,100,000
$210,000 (10%) buyer equity injection; $1,575,000 (75%) SBA 7(a) loan at 10-year term; $315,000 (15%) seller note on 24-month SBA standby, then 5-year repayment at 6% interest.
Asset purchase with MSO entity established by buyer pre-close. Seller signs 18-month paid clinical transition agreement at $200,000 per year. Patient records transferred under HIPAA-compliant BAA. Equipment and lease assigned to MSO. SBA lender requires 3 years of CPA-reviewed financials and seller personal guarantee release tied to 20% equity paydown. Non-compete for seller covers 25-mile radius for 5 years.
Founder Exit via Seller-Financed Asset Purchase — Solo Surgeon Retiring
$1,400,000
$980,000 (70%) SBA 7(a) loan; $280,000 (20%) seller note on full 24-month standby then 60-month repayment at 5.5%; $140,000 (10%) buyer equity injection.
Asset purchase excluding the professional corporation. Buyer establishes a new PC with an associate surgeon hired pre-close. Selling surgeon provides 12-month consulting transition at $10,000 per month included in deal terms. Earnout of $100,000 payable if year-one post-close revenue exceeds $1.2M. Patient database transferred with executed patient consent forms. Non-solicitation clause prevents seller from practicing within 30 miles for 4 years.
Find Cosmetic Surgery Center Businesses For Sale
Pre-screened targets ready for your deal structure — free to join.
Most states prohibit non-physicians from owning or exercising control over a medical professional corporation under corporate practice of medicine (CPOM) laws. In states like California, Texas, and New York, a business entity owned by a non-physician cannot employ physicians or bill for physician services directly. The solution used in nearly all non-physician cosmetic surgery acquisitions is the MSO structure: the non-physician buyer owns the management services organization, which holds all non-clinical assets and employs non-physician staff, while a licensed physician owns the professional corporation that employs providers and renders medical care. The MSO and PC are linked by a management services agreement at a fair-market-value fee, allowing the buyer to capture the economic value of the practice compliantly.
Lower middle market cosmetic surgery centers are generally valued at 3.5x–6x EBITDA, with the specific multiple driven by several factors: the degree of physician key-man dependency, procedure mix diversity (surgical vs. non-surgical recurring revenue), facility accreditation status, malpractice history, staff depth, and growth trajectory. A center generating $1.5M in revenue with $350,000 in EBITDA, diversified procedures, an associate physician, and clean compliance history might trade at 5x–6x ($1.75M–$2.1M). A similarly sized center where the selling surgeon accounts for 80% of revenue and carries an open malpractice claim might trade at 3.5x–4x — or fail to close entirely.
An earnout is a contingent payment tied to post-close business performance — typically revenue or EBITDA over a 1–3 year period. In cosmetic surgery acquisitions, earnouts are used to bridge the valuation gap that arises when a buyer cannot verify whether patient and revenue relationships will transfer after the selling surgeon departs. For example, a buyer might pay $1.8M at close and agree to pay an additional $300,000 if the practice retains 90% of prior-year revenue in year one post-close. Earnouts work best when the seller remains clinically active post-close under a paid employment agreement, the revenue metric is clearly defined (net collections, not gross billings), and the measurement period is short enough to stay within the seller's employment term.
The SBA 7(a) loan program is the most common financing tool for lower middle market cosmetic surgery acquisitions under $5M in purchase price. Buyers typically inject 10% equity, borrow 70–80% from an SBA-approved lender, and negotiate a seller note for the remainder. SBA lenders will require 3 years of practice tax returns and P&Ls, a business valuation from an SBA-approved appraiser, evidence that the practice can service debt from post-close cash flow (typically a 1.25x minimum DSCR), and documentation that physician key-man risk is mitigated — usually through a 12–24 month paid seller transition agreement. Seller notes must be on full standby for the first 24 months of the SBA loan. Practices with heavy add-backs, undocumented cash, or high key-man concentration will face lender scrutiny or require additional collateral.
Malpractice insurance in cosmetic surgery is typically written on a claims-made basis, meaning the policy covers claims filed while the policy is active — not when the procedure was performed. When a selling surgeon retires or leaves the practice, they must purchase tail coverage (also called extended reporting period coverage) to cover any claims filed after the policy lapses for procedures performed during the active policy period. Tail premiums for cosmetic surgeons can range from $50,000 to $150,000 or more depending on specialty, claims history, and coverage limits. In deal negotiations, sellers are typically responsible for funding their own tail coverage. Buyers should require proof of tail purchase as a condition of closing and confirm coverage limits are adequate given the practice's procedure volume and claim history.
Reducing key-man concentration is the single highest-leverage action a selling surgeon can take to increase practice value and deal certainty. Practical steps include hiring and credentialing an associate physician or nurse practitioner 12–24 months before going to market and assigning them a defined patient panel; building out non-surgical revenue lines (injectables, laser, body contouring) that mid-level providers can operate independently; documenting standardized protocols so clinical care is not solely dependent on the founder's judgment; and introducing the associate physician to top patients and referral sources before the sale process begins. Buyers and SBA lenders will discount heavily — or decline entirely — a practice where the departing surgeon represents more than 60–70% of revenue with no clinical succession in place.
More Cosmetic Surgery Center Guides
More Deal Structure Guides
Find the right target, structure the deal, and close with confidence.
Create your free accountNo credit card required
For Buyers
For Sellers